CXCR3 and neoplasm: To evaluate anti-tumor efficacy, we administered 5 × 106 FAP-CAR+, Meso-CAR+ and a comparable number of total MigR control T cells or PBS intravenously in mice when tumors reached a mean volume of 100–150 mm3 (Fig. 1e).